Arrotex’ major new partnership

Arrotex bolsters respiratory portfolio with new Boehringer Ingelheim partnership

Media Release

February 6, 2020

Arrotex Pharmaceuticals Pty Ltd is today announcing a strategic partnership with Boehringer Ingelheim Pty Ltd for the exclusive Australian reseller rights to respiratory products* Spiriva® (tiotropium 18 micrograms powder for inhalation) and Spiriva® HandiHaler®.

Following the 2019 merger of Apotex Australia and Arrow Pharmaceuticals, the combined Arrotex entity now promotes GSK’s Seretide®, Pavtide® (Seretide® authorised generic), Flixotide® and Ventolin® CFC Inhaler brands, along with AstraZeneca’s respiratory brands Symbicort® Turbuhaler®, Symbicort® Rapihaler®, Pulmicort®, Omnaris®, Alvesco®, Bricanyl® and Oxis®.

Arrotex is committed to creating value for Australian community pharmacy. Through innovative partnerships, such as the Boehringer Ingelheim arrangement, Arrotex provides unique branded portfolio offerings for pharmacy to unlock additional revenue.

The partnership with Boehringer Ingelheim will take effect from 10 February 2020 and Apotex and Arrow will soon contact pharmacies with details of commercial arrangements.

Source: Viva Communications.

Check Also

More comprehensive access to glucose monitoring for diabetics

The 58,000 Australians with type 1 diabetes will have access to the Freestyle Libre Flash …